Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Phase I/II clinical trial of regorafenib plus durvalumab MEDI4736 in patients with chemo refractory advanced biliary tract cancers
A Randomized Trial Addressing Cancer-Related Financial Hardship through Delivery of a Proactive Financial Navigation Intervention CREDIT
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
Study Type: Treatment
Phase: III
NCTID: NCT03533582
Principal Investigator:
Keith August
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician?s Choice in Subjects with Fibroblast Growth Factor Receptor FGFR-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma FIRST-308
A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma
Study Type: Treatment
Phase: II
NCTID: NCT06050252
Principal Investigator:
Raed Al-Rajabi
Phase III Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib E7080/MK-7902 in Combination with Pembrolizumab MK-3475 Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma LEAP-002
A Long-term Follow-up Master Protocol for Participants who Received Cell or Gene Therapies in Other AstraZeneca Studies LOCUS
Study Type: Supportive Care
Phase: IV
NCTID: NCT06194461
Principal Investigator:
Raed Al-Rajabi
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization TACE in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma EMERALD-1
A prospective, multicenter, open-label single arm study evaluating the safety and efficacy of selective internal radiation therapy SIRT using SIR-Spheres Y-90 resin microspheres on duration of response DoR and objective response rate ORR in unresectable hepatocellular carcinoma HCC patients DOORwaY90 Study
Study Type: Treatment
Phase: Device
NCTID: NCT04736121
Principal Investigator:
Zachary Collins